<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20211102</date><key>pmc.key</key><document><id>8555961</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1016/j.addbeh.2021.107092</infon><infon key="article-id_pii">S0306-4603(21)00277-X</infon><infon key="article-id_pmc">8555961</infon><infon key="article-id_pmid">34469783</infon><infon key="article-id_publisher-id">107092</infon><infon key="fpage">107092</infon><infon key="kwd">Cannabis Behavioral economics Demand Motives</infon><infon key="license">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key="lpage">107092</infon><infon key="name_0">surname:Vedelago;given-names:L.</infon><infon key="name_1">surname:Wardell;given-names:J.D.</infon><infon key="name_2">surname:Kempe;given-names:T.</infon><infon key="name_3">surname:Patel;given-names:H.</infon><infon key="name_4">surname:Amlung;given-names:M.</infon><infon key="name_5">surname:MacKillop;given-names:J.</infon><infon key="name_6">surname:Keough;given-names:M.T.</infon><infon key="section_type">TITLE</infon><infon key="title">Keywords</infon><infon key="type">front</infon><infon key="volume">124</infon><infon key="year">2021</infon><offset>0</offset><text>Getting high to cope with COVID-19: Modelling the associations between cannabis demand, coping motives, and cannabis use and problems</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>134</offset><text>During the COVID-19 pandemic, people may use substances like cannabis for enhancement or coping purposes. Behavioral economic demand for a substance is a key determinant of its use and misuse and can be measured via hypothetical purchase tasks. Previous research suggests that motivations to use a substance play a mediational role between elevated substance demand and problems, but comparable mechanistic research has yet to be done in the COVID-19 context and on the effects of cannabis demand on cannabis use patterns. Participants (n = 137) were recruited via the online crowdsourcing platform Prolific. Participants completed measures of cannabis use and problems, motivations for cannabis use, and the Marijuana Purchase Task. Two indices of demand, Persistence (i.e., sensitivity to increasing cost of cannabis) and Amplitude (i.e., consumption of cannabis at unrestricted cost), were related to increased cannabis problems via the use motive of coping during the COVID-19 pandemic. This model did not support the mediational role of enhancement motives. Those with increased cannabis demand who tend to use cannabis to cope are at increased risk of experiencing negative cannabis-related consequences during the COVID-19 pandemic.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1376</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1389</offset><text>Amid the pandemic caused by the novel coronavirus disease (COVID-19), public health measures were enacted in countries around the world to curb the spread of COVID-19. In Canada, wide-scale emergency measures were put in place in March 2020 that severely impacted Canadians’ ability to engage in work, educational, recreational, and social activities. During times of high stress and anxiety, social isolation, and limited out-of-home recreational activities such as those seen during the COVID-19 pandemic, people may increase their use of substances like cannabis. Cannabis is the most widely used psychoactive substance besides alcohol in Canada, and its use can be accompanied by the risk of developing a cannabis use disorder along with numerous short-term and long-term adverse health consequences. Alongside the implementation of COVID-19-related emergency measures, a Statistics Canada survey reported a sharp increase in cannabis sales in March and April 2020 compared with previous months. Further, a survey of Canadian adults found that among cannabis users, approximately half increased their use of cannabis relative to their pre-pandemic consumption patterns. The widespread use of cannabis and an increase in use during the current COVID-19 pandemic underscores the necessity of understanding the etiology of elevated levels of cannabis use.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2748</offset><text>A key determinant of a substance’s use and misuse is its reinforcing value, which refers to its behavior-strengthening and behavior-maintaining properties. The reinforcing value of a substance has been operationalized as behavioral economic demand, or the relationship between the price of a substance and its consumption. Substance-related demand has been measured in the lab through the use of hypothetical purchase tasks. Purchase tasks have been employed across a number of substances including alcohol, tobacco, and cocaine, and more recently for cannabis (i.e., Marijuana Purchase Task). These tasks ask the participant to estimate their consumption of a substance at varying price points (e.g., “How many hits of marijuana would you take if they were $2.00?”). Purchase tasks allow for the characterization of an individual’s pattern of demand via the calculation of several demand indices: four observed indices (intensity, Omax, Pmax, and breakpoint) and one derived index (elasticity). Intensity refers to unconstrained consumption at zero cost. Omax refers to the peak expenditure, or the maximum total amount of money spent on the substance across price points. Pmax is the price at which this peak expenditure occurs. Breakpoint refers to the cost at which consumption is suppressed to zero. Higher values on each of these indices reflect higher demand for the substance. The derived index, elasticity, refers to the rate at which consumption decreases relative to increases in cost. Latent factor analysis of the Marijuana Purchase Task has revealed that these five indices map onto two underlying dimensions of demand. The first factor is “Amplitude,” which refers to consumption at unrestricted cost and is comprised of one index, intensity. Higher consumption at zero cost reflects higher demand. The second factor, “Persistence,” is comprised of Omax, Pmax, breakpoint, and elasticity, and reflects the individual’s sensitivity to increasing cost. A low sensitivity to increasing cost indicates higher demand. This factor structure aligns with research demonstrating a similar structure for alcohol and tobacco purchase tasks.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4911</offset><text>Responses on hypothetical purchase tasks have been shown to be an accurate reflection of demand for the real substance, as well as a key determinant of patterns of use and misuse. For cannabis specifically, higher Amplitude is associated with increased cannabis use quantity and frequency, increased craving, and more symptoms of cannabis dependence. Higher Persistence is associated with fewer stop attempts or attempts to cut down on cannabis use. Increased demand for cannabis has also been linked to hazardous behaviors, such as driving after using cannabis. Efforts have been made to identify and better understand the etiological and maintaining factors of substance use disorders (e.g., the Addictions Neuroclinical Assessment). However, currently there is little research on which mechanisms explain the relationship of greater demand for cannabis with its use and associated problems</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5804</offset><text>One potentially relevant factor that may account for the relationship between cannabis demand and outcomes is specific motives for use. Previous research has indicated that for other substances like alcohol, substance demand and specific motives for use are both implicated in consumption and related problems. Those with elevated demand may be more likely to use cannabis for specific reasons or under particular circumstances. Understanding the specific motives for substance use can shed light on when and how much someone is likely to use as well as the potential consequences of their use. Motives for cannabis use generally vary along two dimensions: valence (i.e., positive or negative) and source of reinforcement (i.e., internal or external). The internal motives of coping and mood enhancement appear to be especially related to negative outcomes, showing associations with worse mental health functioning, greater quantities of cannabis use, and more cannabis-related problems. Research with alcohol demand has indicated that the demand indices of intensity (unconstrained consumption at zero cost) and Omax (maximum expenditure on substance) are positively related with alcohol use and problems, and this relationship is mediated by elevated motives of enhancement and coping. Additionally, a study among veterans demonstrated that those with a high valuation of alcohol were more likely to use alcohol for coping and enhancement motives, which in turn predicted more alcohol-related consequences. Enhancement and coping motives for use are relevant to the COVID-19 pandemic, as individuals with higher levels of demand may be at higher risk of escalating substance use to alleviate the elevated levels of boredom or negative affect. Previous meta-analytic research has demonstrated this contextual link, with alcohol demand indices showing significant increases following stress- or negative affect-inducing paradigms. The extant literature suggests that motivations to use play a mediational role between elevated substance demand and problems, but comparable mechanistic research has yet to be done on the effects of cannabis demand on cannabis use patterns. This is an especially important area to explore as we see increased levels of cannabis use as the COVID-19 pandemic continues.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8105</offset><text>The current study is the first to our knowledge to investigate internal cannabis use motives as a potential mediating factor between cannabis demand pre-declaration of COVID-19 emergency measures and cannabis use patterns and problems after the implementation of COVID-19 emergency measures in Canada. To do this, we used a crowdsourcing platform (i.e., Prolific) to examine how pre-existing levels of cannabis demand related to changes in cannabis use and problems during the first 30 days of the COVID-19 state of emergency. Then, we examined the mediating role of internal motives (coping and enhancement). We hypothesized that higher levels of cannabis demand pre-COVID-19 may lead to greater coping or enhancement motives to use cannabis during the COVID-19 pandemic and associated emergency measures. Further, we hypothesized that this mechanism may lead to increased cannabis use and/or problems after the enactment of COVID-19 emergency measures.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>9061</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9069</offset><text>Participants and procedure</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9096</offset><text>Participants for the study were recruited through Prolific. Prolific is an online recruiting platform where individuals are able to access and complete a host of surveys and studies run by researchers. Prolific ensures the application of proper recruitment standards and informing participants on their role in research. Data were drawn from a larger study of alcohol use during the COVID-19 pandemic among Canadian adults. Four attention check items, as recommended by Prolific’s guidelines, were implemented in this study to ensure data quality (e.g., “Please answer this question by choosing option number two, ‘disagree’.”). Participants’ data were automatically excluded from the study if they failed 2 or more attention checks and completed all questions in an unrealistically short time (defined as under 20 min in this study; n = 2). Of the 400 remaining participants, we selected a subsample that endorsed having used any type of cannabis in the past three months (n = 159) for the present analyses. Participants’ data were further excluded for missing (n = 2) or non-systematic (n = 20) data on the Marijuana Purchase Task (see measures). The final sample was comprised of 137 participants.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10320</offset><text>Data collection was completed from April 30, 2020 to May 4, 2020, approximately 7–8 weeks after the COVID-19 pandemic was declared. A majority of the measures required participants to respond to items by referencing either a month prior to the COVID-19 state of emergency in their area or in reference to the past month (i.e., in the past 30 days, which occurred during COVID-19 states of emergency and restrictions). This study was approved by York University’s Office of Research Ethics. All participants were given $13 CAD as compensation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10869</offset><text>Measures</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>10878</offset><text>Demographics</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10891</offset><text>Participants were asked to report relevant demographic information, including their age, sex, race/ethnicity, level of education, annual household income, and relationship status. Current living situation and employment status prior to the COVID-19 pandemic were also reported.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>11169</offset><text>Cannabis use frequency</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11192</offset><text>A question derived from the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU) was used to assess the frequency of cannabis use. Two versions of the question were administered; the first required participants to answer in the context of the one-month period prior to the declaration of the COVID-19 emergency in their area, and the second asked participants to refer to their cannabis use in the past month (30 days). Participants responded using a 9-point Likert scale (0 = I did not use cannabis to 8 = More than once per day).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>11766</offset><text>Motives for cannabis use</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11791</offset><text>The Marijuana Motives Measure (MMM; 25 items) assessed self-reported reasons for which participants use cannabis. Participants responded using a 5-point scale (1 = Almost Never/Never to 5 = Almost Always/Always) based on how frequently in the past month (30 days) their cannabis use was motivated by each of the presented items. The MMM encompasses five domains of motives for cannabis use (i.e., enhancement, conformity, expansion, coping, and social motives), and previous research has provided support for the validity and internal consistency of this measure. Cronbach’s alphas for the scales used for the current sample were 0.91 (coping) and 0.90 (enhancement).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>12466</offset><text>Pre-covid cannabis use problems</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12498</offset><text>The Cannabis Use Disorder Identification Test Revised (CUDIT-R, 8 items) screened for symptoms of cannabis use disorder over the past 6 months and was included as a covariate in order to control for pre-existing cannabis problems (before COVID-19). The sum score was calculated from participant responses, reflecting cannabis use and problems. Cronbach’s alpha for the current sample was 0.77.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>12895</offset><text>Past 30 days cannabis use problems</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12930</offset><text>The Marijuana Problems Scale (MPS, 19 items) was administered to assess for the extent of cannabis-related problems over the past 30 days (e.g., “Has cannabis caused you to have lower productivity”, “Has cannabis caused you withdrawal symptoms”). (Items on the MPS are answered via a 3-point scale (0 = No problem to 2 = Serious problem), and the sum score from each participant was used to evaluate this domain. Cronbach’s alpha for the current sample was 0.85.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>13408</offset><text>Cannabis demand</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13424</offset><text>Participants completed the Marijuana Purchase Task (MPT) to measure individual behavioral economic demand for cannabis, which has been adapted from demand paradigms for other substances. The MPT asks individuals to think of a typical day when they would use cannabis and was modified for the present study to refer a typical day during the one-month period prior to the COVID-19 state of emergency in their area. Participants are then asked to imagine they only have access to purchase cannabis from the source being presented to them and are given other parameters relevant to the providing source (e.g., ‘there are 10 hits of marijuana in a joint’; ‘you would consume all of the marijuana you request in a day’; ‘the cannabis is of average quality’). Participants are then asked, based on these conditions, to indicate the “number of hits” they would take on an ordinary day at 22 escalating price points (which range from $0 to $10).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>14377</offset><text>Data analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14391</offset><text>All analyses for the study were conducted in SPSS Version 27 and MPlus Version 8.0. The first step in the data analysis was computing the MPT indices. The MPT data were screened for completeness and participants with any missing data were excluded (n = 2). MPT data were then evaluated for non-systematic responding according to the criteria proposed by. Four participants’ data violated the trend criterion, and one additional participant’s data violated both the bounce and reversal criteria and were thus excluded. Because the calculation of elasticity requires variation in consumption across prices, participants whose data did not conform to demand curves (i.e., due to no reported consumption across prices or rectangular demand) were excluded (n = 15). The four observed demand indices were then calculated and outlying values (i.e., ≥ 3.29 standard deviations above the mean) were recoded to be one unit higher than the next highest non-outlying value. &lt; 2% of scores were winsorized. Values of 0 were set to an arbitrarily low value of 0.01 to allow for demand curve analyses. Elasticity (denoted as α) was modeled using nonlinear exponential demand curve model in GraphPad Prism 7: log10Q = log10  Q0 + k(e−αQ0P  – 1). In this model, Q = log units’ consumption, Q0 = mean consumption at zero cost, P = price, and k = range of log units consumption. Based on mean performance, the overall best-fitting k parameter was determined to be 2.0 and used for all individual demand curves. The inverse value for elasticity (i.e., 1/α) was used to make interpretation more intuitive, aligning with previous work. Persistence was calculated as the mean of the standardized values of 1/α, Pmax, Omax, and breakpoint. Amplitude was defined as the participants’ intensity value.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16203</offset><text>Following computation of the MPT Amplitude and persistence scores, bivariate correlations and descriptive statistics were inspected for all substantive path model variables. Next, a path model was conducted, specifying pre-COVID persistence and Amplitude factors as correlated predictors; past 30 days (during COVID) coping and enhancement motives for cannabis use as correlated mediators; and past 30 days cannabis use frequency and related problems as correlated outcomes. Pre-COVID cannabis frequency and pre-COVID level of cannabis use problems (as measured by the CUDIT) were controlled for in the model. Before running the main path model, we examined the normality of all variables. While all variables showed acceptable skew (&lt; 3.0) and kurtosis (&lt; 8.0) values, some showed slight positively skew. To correct for this, we used robust maximum likelihood estimation to estimate the model, as well as bias-corrected bootstrapped confidence intervals (CI) to test the presence of indirect effects. Both MLR and boostrapping have been shown to be robust against violations of normality. Mediation was considered supported if the indirect effect 95% CI did not contain zero. Model fit of the hypothesized mediation path model was considered good if the CFI was greater than 0.95, the RMSEA was ≤ 0.08, SRMR ≤ 0.08, and the model χ2 was non-statistically significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>17585</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17593</offset><text>Descriptive statistics and bivariate correlations</text></passage><passage><infon key="file">t0005.xml</infon><infon key="id">t0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>17643</offset><text>Descriptive statistics and bivariate correlations.</text></passage><passage><infon key="file">t0005.xml</infon><infon key="id">t0005</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;&lt;bold&gt;M (SD)&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;%&lt;/bold&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Age&lt;/td&gt;&lt;td&gt;30.98 (9.47)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Gender&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Man&lt;/td&gt;&lt;td/&gt;&lt;td&gt;54.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Woman&lt;/td&gt;&lt;td/&gt;&lt;td&gt;44.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Other&lt;/td&gt;&lt;td/&gt;&lt;td&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Ethnicity&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Caucasian/White&lt;/td&gt;&lt;td/&gt;&lt;td&gt;73.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; East Asian/South-East Asian/Pacific Islander&lt;/td&gt;&lt;td/&gt;&lt;td&gt;13.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; South Asian&lt;/td&gt;&lt;td/&gt;&lt;td&gt;7.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Hispanic/Latino&lt;/td&gt;&lt;td/&gt;&lt;td&gt;5.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Middle Eastern/North African/Central Asian&lt;/td&gt;&lt;td/&gt;&lt;td&gt;4.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Black&lt;/td&gt;&lt;td/&gt;&lt;td&gt;2.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Aboriginal&lt;/td&gt;&lt;td/&gt;&lt;td&gt;1.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Other&lt;/td&gt;&lt;td/&gt;&lt;td&gt;2.9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Province/Territory&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Ontario&lt;/td&gt;&lt;td/&gt;&lt;td&gt;54.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Alberta&lt;/td&gt;&lt;td/&gt;&lt;td&gt;12.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; British Columbia&lt;/td&gt;&lt;td/&gt;&lt;td&gt;10.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Quebec&lt;/td&gt;&lt;td/&gt;&lt;td&gt;10.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; New Brunswick&lt;/td&gt;&lt;td/&gt;&lt;td&gt;2.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Newfoundland and Labrador&lt;/td&gt;&lt;td/&gt;&lt;td&gt;2.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Nova Scotia&lt;/td&gt;&lt;td/&gt;&lt;td&gt;2.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Saskatchewan&lt;/td&gt;&lt;td/&gt;&lt;td&gt;2.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Manitoba&lt;/td&gt;&lt;td/&gt;&lt;td&gt;1.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Prince Edward Island&lt;/td&gt;&lt;td/&gt;&lt;td&gt;1.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Yukon&lt;/td&gt;&lt;td/&gt;&lt;td&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Northwest Territories&lt;/td&gt;&lt;td/&gt;&lt;td&gt;0.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Nunavut&lt;/td&gt;&lt;td/&gt;&lt;td&gt;0.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Annual Household Income&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Less than $20,000&lt;/td&gt;&lt;td/&gt;&lt;td&gt;10.9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; $20,000 - $39,000&lt;/td&gt;&lt;td/&gt;&lt;td&gt;13.9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; $40,000 - $59,000&lt;/td&gt;&lt;td/&gt;&lt;td&gt;13.9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; $60,000 - $79,000&lt;/td&gt;&lt;td/&gt;&lt;td&gt;10.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; $80,000 - $99,999&lt;/td&gt;&lt;td/&gt;&lt;td&gt;20.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; $100,000 - $149,999&lt;/td&gt;&lt;td/&gt;&lt;td&gt;21.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; $150,000 - $199,999&lt;/td&gt;&lt;td/&gt;&lt;td&gt;4.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Over $200,000&lt;/td&gt;&lt;td/&gt;&lt;td&gt;4.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Have children&lt;/td&gt;&lt;td/&gt;&lt;td&gt;27&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Primary form of cannabis used&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Marijuana (i.e., dried bud/leaf of plant)&lt;/td&gt;&lt;td/&gt;&lt;td&gt;72.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Concentrates (e.g., oil, wax, shatter)&lt;/td&gt;&lt;td/&gt;&lt;td&gt;8.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Edibles&lt;/td&gt;&lt;td/&gt;&lt;td&gt;16.9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Other&lt;/td&gt;&lt;td/&gt;&lt;td&gt;2.1&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>17694</offset><text>	M (SD)	%	 	Age	30.98 (9.47)		 	Gender			 	 Man		54.7	 	 Woman		44.5	 	 Other		0.7	 	Ethnicity			 	 Caucasian/White		73.7	 	 East Asian/South-East Asian/Pacific Islander		13.1	 	 South Asian		7.3	 	 Hispanic/Latino		5.8	 	 Middle Eastern/North African/Central Asian		4.4	 	 Black		2.2	 	 Aboriginal		1.5	 	 Other		2.9	 	Province/Territory			 	 Ontario		54.7	 	 Alberta		12.4	 	 British Columbia		10.2	 	 Quebec		10.2	 	 New Brunswick		2.2	 	 Newfoundland and Labrador		2.2	 	 Nova Scotia		2.2	 	 Saskatchewan		2.2	 	 Manitoba		1.5	 	 Prince Edward Island		1.5	 	 Yukon		0.7	 	 Northwest Territories		0.0	 	 Nunavut		0.0	 	Annual Household Income			 	 Less than $20,000		10.9	 	 $20,000 - $39,000		13.9	 	 $40,000 - $59,000		13.9	 	 $60,000 - $79,000		10.2	 	 $80,000 - $99,999		20.4	 	 $100,000 - $149,999		21.2	 	 $150,000 - $199,999		4.4	 	 Over $200,000		4.4	 	Have children		27	 	Primary form of cannabis used			 	 Marijuana (i.e., dried bud/leaf of plant)		72.5	 	 Concentrates (e.g., oil, wax, shatter)		8.5	 	 Edibles		16.9	 	 Other		2.1	 	</text></passage><passage><infon key="file">t0005.xml</infon><infon key="id">t0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>18778</offset><text>Note. Ethnicity percentage values sum to greater than 100% as participants were able to endorse more than one option.</text></passage><passage><infon key="file">t0010.xml</infon><infon key="id">t0010</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>18896</offset><text>Descriptive statistics and bivariate correlations.</text></passage><passage><infon key="file">t0010.xml</infon><infon key="id">t0010</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;&lt;bold&gt;1&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;2&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;3&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;4&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;5&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;6&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;7&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;8&lt;/bold&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;1. Persistence (Pre-COVID)&lt;/td&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;0.299**&lt;/td&gt;&lt;td&gt;0.425**&lt;/td&gt;&lt;td&gt;0.410**&lt;/td&gt;&lt;td&gt;0.154&lt;/td&gt;&lt;td&gt;0.105&lt;/td&gt;&lt;td&gt;0.169*&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0.256**&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;2. Amplitude (Pre-COVID)&lt;/td&gt;&lt;td/&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;0.572**&lt;/td&gt;&lt;td&gt;0.425**&lt;/td&gt;&lt;td&gt;0.521**&lt;/td&gt;&lt;td&gt;0.489**&lt;/td&gt;&lt;td&gt;0.379**&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0.203**&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;3. Coping Motives (Post-COVID)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;0.620**&lt;/td&gt;&lt;td&gt;0.444**&lt;/td&gt;&lt;td&gt;0.494**&lt;/td&gt;&lt;td&gt;0.572**&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0.478**&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;4. Enhancement Motives (Post-COVID)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;0.390**&lt;/td&gt;&lt;td&gt;0.375**&lt;/td&gt;&lt;td&gt;0.493**&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0.318**&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;5. Cannabis Use (Pre-COVID)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;0.801**&lt;/td&gt;&lt;td&gt;0.703**&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0.363**&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;6. Cannabis Use (Post-COVID)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;0.709**&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0.347**&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;7. CUDIT (Pre-COVID)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td&gt;–&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0.631**&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;8. Cannabis Problems (Post-COVID)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;char&quot;&gt;–&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;italic&gt;M&lt;/italic&gt;&lt;/td&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;9.723&lt;/td&gt;&lt;td&gt;2.171&lt;/td&gt;&lt;td&gt;2.847&lt;/td&gt;&lt;td&gt;3.088&lt;/td&gt;&lt;td&gt;3.214&lt;/td&gt;&lt;td&gt;6.197&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;2.553&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;italic&gt;SD&lt;/italic&gt;&lt;/td&gt;&lt;td&gt;–&lt;/td&gt;&lt;td&gt;12.449&lt;/td&gt;&lt;td&gt;1.157&lt;/td&gt;&lt;td&gt;1.236&lt;/td&gt;&lt;td&gt;2.477&lt;/td&gt;&lt;td&gt;2.774&lt;/td&gt;&lt;td&gt;5.313&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;3.878&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;italic&gt;Range&lt;/italic&gt;&lt;/td&gt;&lt;td&gt;−1.85–2.50&lt;/td&gt;&lt;td&gt;0–51&lt;/td&gt;&lt;td&gt;1–5&lt;/td&gt;&lt;td&gt;1–5&lt;/td&gt;&lt;td&gt;0–8&lt;/td&gt;&lt;td&gt;0–8&lt;/td&gt;&lt;td&gt;0–22&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0–15.26&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;italic&gt;Skew&lt;/italic&gt;&lt;/td&gt;&lt;td&gt;0.90&lt;/td&gt;&lt;td&gt;2.23&lt;/td&gt;&lt;td&gt;0.71&lt;/td&gt;&lt;td&gt;−0.07&lt;/td&gt;&lt;td&gt;0.72&lt;/td&gt;&lt;td&gt;0.57&lt;/td&gt;&lt;td&gt;1.06&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;2.14&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;italic&gt;Kurtosis&lt;/italic&gt;&lt;/td&gt;&lt;td&gt;0.29&lt;/td&gt;&lt;td&gt;4.37&lt;/td&gt;&lt;td&gt;−0.76&lt;/td&gt;&lt;td&gt;−1.20&lt;/td&gt;&lt;td&gt;−0.68&lt;/td&gt;&lt;td&gt;−1.15&lt;/td&gt;&lt;td&gt;0.35&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;5.36&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>18947</offset><text>	1	2	3	4	5	6	7	8	 	1. Persistence (Pre-COVID)	–	0.299**	0.425**	0.410**	0.154	0.105	0.169*	0.256**	 	2. Amplitude (Pre-COVID)		–	0.572**	0.425**	0.521**	0.489**	0.379**	0.203**	 	3. Coping Motives (Post-COVID)			–	0.620**	0.444**	0.494**	0.572**	0.478**	 	4. Enhancement Motives (Post-COVID)				–	0.390**	0.375**	0.493**	0.318**	 	5. Cannabis Use (Pre-COVID)					–	0.801**	0.703**	0.363**	 	6. Cannabis Use (Post-COVID)						–	0.709**	0.347**	 	7. CUDIT (Pre-COVID)							–	0.631**	 	8. Cannabis Problems (Post-COVID)								–	 	M	–	9.723	2.171	2.847	3.088	3.214	6.197	2.553	 	SD	–	12.449	1.157	1.236	2.477	2.774	5.313	3.878	 	Range	−1.85–2.50	0–51	1–5	1–5	0–8	0–8	0–22	0–15.26	 	Skew	0.90	2.23	0.71	−0.07	0.72	0.57	1.06	2.14	 	Kurtosis	0.29	4.37	−0.76	−1.20	−0.68	−1.15	0.35	5.36	 	</text></passage><passage><infon key="file">t0010.xml</infon><infon key="id">t0010</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19779</offset><text>Note. M, mean; SD, standard deviation.</text></passage><passage><infon key="file">t0010.xml</infon><infon key="id">t0010</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19818</offset><text>* p &lt; .05, ** p &lt; .01</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19844</offset><text>The sample was 44.5% female, with a mean age of 30.98 years (SD = 9.47). For further participant demographics see Table 1 . Participants generally had not increased their frequency of cannabis use from pre-COVID to past 30 days (during COVID), using cannabis between once and twice a week on average during both periods. With regard to scores on the CUDIT, 35.2% of participants fell above the cut-off for hazardous cannabis use (sum score of ≤ 8), and 20.5% fell above the cut-off for possible cannabis use disorder (sum score of ≤ 12). 71.5% of the sample used cannabis for solely recreational purposes and 28.5 used either solely for medicinal reasons or for both medicinal and recreational reasons. Both Persistence and Amplitude were significantly correlated with past 30 days cannabis problems, and Amplitude was significantly correlated with past 30 days cannabis use frequency (see Table 2 ).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20759</offset><text>Hypothesis testing: Mediation analysis</text></passage><passage><infon key="file">gr1_lrg.jpg</infon><infon key="id">f0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>20798</offset><text>Mediated path model from pre-COVID cannabis demand (Persistence and Amplitude) to post-COVID frequency of cannabis use and problems via post-COVID internal motives for cannabis use (coping and enhancement). Standardized coefficients with standard errors (in brackets) are presented. Solid lines and asterisks denote statistically significant paths (p &lt; .05) and gray lines are non-statistically significant paths (p &gt; .05).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21226</offset><text>The initial hypothesized model (Fig. 1 ) provided a very good to excellent fit to the data (χ2 = 14.30, df = 8, p = .074, CFI = 0.983; RMSEA = 0.070 (90% CI [0.000, 0.128]); SRMR = 0.030) and therefore this model was retained and interpreted. Both pre-COVID Persistence and Amplitude facets of cannabis-related demand were positive predictors of both post-COVID coping and enhancement motives. Post-COVID coping motives positively predicted post-COVID cannabis problems (controlling for pre-COVID CUDIT scores), but not post-COVID frequency of cannabis use (controlling for pre-COVID frequency). Post-COVID enhancement motives did not predict frequency of cannabis use or cannabis problems post-pandemic lockdown.1 In tems of effect size, the two cannabis demand facets explained 49% and 38% in coping and enhancement motives, respectively. The model explained large proportions of variance in both post-COVID cannabis use (75%) and problems (43%).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22188</offset><text>Regarding mediation effects, two main indirect effects were supported in the model. First, we observed that post-COVID coping motives mediated the effect of pre-COVID cannabis persistence on post-COVID cannabis problems (β = 0.059, 95%CI = 0.003, 0.115). Second and similarly, we also observed that post-COVID coping motives mediated the impact of pre-COVID Amplitude on post-lockdown cannabis problems (β = 0.053, 95%CI = 0.002, 0.104). Overall, our findings suggest that individuals with higher levels of pre-COVID cannabis demand experienced a greater number of cannabis-related problems during the initial stages of the pandemic as a function of their higher coping motives for use.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>22885</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22896</offset><text>The present study is among the first to investigate mediational pathways to cannabis use and problems during the COVID-19 pandemic. We aimed to understand the role of indices of cannabis demand on motives for use and patterns of cannabis use and misuse. Previous research has indicated that individual differences in substance demand is a pre-existing factor that may place an individual at vulnerability for increased substance use and problems (e.g.,). In line with previous alcohol demand research, we hypothesized that internal motives for cannabis use, specifically coping and enhancement, may mediate this relationship. Our results indicate that two indices of demand, Persistence and Amplitude, were related to increased cannabis problems via the use motive of coping during the COVID-19 pandemic. This model did not support the role of enhancement motives. This finding indicates that those with increased cannabis demand who tend to use cannabis to cope are at increased risk of experiencing negative cannabis-related consequences. This is largely in line with previous research implicating increased cannabis demand in increased cannabis craving, use quantity and frequency, and dependence symptoms. Of particular note is the finding that the demand facet of Persistence was implicated in this model. Previous research has indicated that Amplitude was more associated with increased cannabis use and cannabis-related problems. This difference in finding may be attributable to differences in sample characteristics. The participants in recruited pre-pandemic from Rhode Island, a U.S. state in which recreational cannabis use is illegal. In contrast, participants in the current study were from across Canada during the COVID-19 pandemic, a country in which recreational cannabis use has been legal for over two years.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24725</offset><text>Elevated cannabis demand appears to be a vulnerability factor for experiencing cannabis-related problems, and as such early identification and prevention efforts should be targeted at these individuals. This is especially relevant as the COVID-19 pandemic continues, with its associated unprecedented levels of stress and anxiety, both about the virus itself as well as caused by the associated lockdowns and emergency measures,. Cannabis use has been well-established as a method to cope with stress for some, and this method may be especially salient to those individuals who perceive cannabis to have a higher reinforcement value. Using cannabis to cope is especially relevant in the context of a largescale external stressor like the COVID-19 pandemic. Other research has shown that COVID-19-related worry is associated with using cannabis to cope. Those that use cannabis to deal with stressors may be more likely to experience heavier cannabis use and more cannabis-related problems. Specifically focusing cannabis interventions on skills for coping with general and traumatic stress might be an important target to improve treatment outcomes. In extreme situations like the COVID-19 pandemic and associated lockdowns in which access to formal interventions might be limited, encouraging stress-reducing activities like exercise and yoga may be beneficial. Broadly, encouraging the use of more adaptive coping strategies rather than cannabis use is a clear implication of the current research.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26225</offset><text>The findings of this study must be considered in light of certain limitations. The most significant limitation is the use of cross-sectional data to test a mediational model, and therefore being unable to determine the temporal precedence of variables. Despite this limitation, participants reported their pre-pandemic cannabis use so that we were able to control for retrospective use. The current research is also limited to the initial period of the pandemic. Since restrictions have been variously lifted and re-implemented in response to COVID-19 case counts, it is important to examine longer term effects of the pandemic on cannabis used and the role of demand using a longitudinal model. Furthermore, the sample size for the current study is modest for testing the hypothesized path model. However, our large R2 effect sizes suggest that we captured strong predictors of cannabis motives and problems during COVID-19 in our study. Next, since the MPT is a measure of hypothetical consumption of cannabis, actual cannabis consumption is not measured by this task. However, previous research has provided evidence for the validity of hypothetical purchase tasks for other substances (i.e., alcohol and tobacco). Future research is needed to support the validity of the MPT. Moreover, the MPT instructional set refers to smoking “hits” of cannabis, which may impact its use among those whose primary form of cannabis use is vaping or consuming edibles. Though the majority of the sample in the current study indicated that dried cannabis was their primary form of use, this presents a clear limitation to the ecological validity of the MPT. Recent qualitative research on the MPT has recommended against the use of the term “hits” in favor of “grams” and that the specific mode of cannabis administration be incorporated into future iterations of the MPT. A further potential limitation is that the study measures were administered online rather than in a laboratory context. This presents several drawbacks when administering the MPT, namely that the research team was not able to emphasize important parts of the instructions or answer questions; it is possible that participants’ performance was impacted in a negative way by these factors. Also, because our sample was drawn from a larger sample of Canadian drinkers it is possible that cannabis use motives in our sample may have differed systematically from those of cannabis-only users. Co-use of cannabis and alcohol is associated with elevated alcohol demand, so it is possible that co-use may also systematically impact both cannabis demand and motives for use. Finally, we acknowledge that our sample had a rather high level of income (greater than 50% of participants reported an annual household income &gt; $80,000). While household income was unrelated to cannabis use variables in this study, our findings may not generalize to samples with lower income.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29162</offset><text>In conclusion, this study replicates a modest body of previous research linking cannabis demand to cannabis-related problems and provides evidence for the role of coping motives in the increased cannabis-related problems experienced by those with elevated cannabis demand. Further research is needed to replicate this research within a sample of cannabis-only users and in a real-world, offline setting. This research will inform best practices for targeted problematic cannabis use interventions.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>29660</offset><text>Author disclosure statements</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_2</infon><offset>29689</offset><text>Role of Funding Sources</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>29713</offset><text>Funding for this study was provided by York University start-up funds awarded to Dr. Matthew Keough. York University had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_2</infon><offset>29992</offset><text>Contributors</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>30005</offset><text>Matthew Keough and Jeffrey Wardell designed the study and wrote the protocol. Tyler Kempe conducted data collection. Lana Vedelago and Matthew Keough conceptualized the research question and conducted the statistical analysis. Herry Patel, Michael Amlung, and James MacKillop assisted with data analysis. Lana Vedelago wrote the first draft of the manuscript and all authors contributed to the edit and review of the manuscript. All authors have approved of the final manuscript.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_2</infon><offset>30485</offset><text>Conflict of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>30506</offset><text>James MacKillop is a principal in BEAM Diagnostics Inc., but no BEAM products were used in the data collected. All other authors declare that they have no conflicts of interest.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>30684</offset><text>CRediT authorship contribution statement</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>30725</offset><text>L. Vedelago: Conceptualization, Validation, Formal analysis, Visualization, Writing – original draft. J.D. Wardell: Methodology, Writing – review &amp; editing. T. Kempe: Data curation, Writing – review &amp; editing. H. Patel: Methodology, Writing – review &amp; editing. M. Amlung: Writing – review &amp; editing. J. MacKillop: Writing – review &amp; editing. M.T. Keough: Conceptualization, Data curation, Formal analysis, Investigation, Resources, Supervision, Writing – review &amp; editing.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>31212</offset><text>Declaration of Competing Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>31246</offset><text>JM is a principal in BEAM Diagnostics Inc., but no BEAM products were used in the the data collected. No other authors have declarations.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>31384</offset><text>References</text></passage><passage><infon key="fpage">817</infon><infon key="issue">5</infon><infon key="lpage">831</infon><infon key="name_0">surname:Acuff;given-names:S.F.</infon><infon key="name_1">surname:Amlung;given-names:M.</infon><infon key="name_2">surname:Dennhardt;given-names:A.A.</infon><infon key="name_3">surname:MacKillop;given-names:J.</infon><infon key="name_4">surname:Murphy;given-names:J.G.</infon><infon key="pub-id_doi">10.1111/add.14865</infon><infon key="pub-id_pmid">31656048</infon><infon key="section_type">REF</infon><infon key="source">Addiction</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">2020</infon><offset>31395</offset><text>Experimental manipulations of behavioral economic demand for addictive commodities: A meta-analysis</text></passage><passage><infon key="fpage">137</infon><infon key="issue">1–2</infon><infon key="lpage">143</infon><infon key="name_0">surname:Adamson;given-names:S.J.</infon><infon key="name_1">surname:Kay-Lambkin;given-names:F.J.</infon><infon key="name_2">surname:Baker;given-names:A.L.</infon><infon key="name_3">surname:Lewin;given-names:T.J.</infon><infon key="name_4">surname:Thornton;given-names:L.</infon><infon key="name_5">surname:Kelly;given-names:B.J.</infon><infon key="name_6">surname:Sellman;given-names:J.D.</infon><infon key="pub-id_doi">10.1016/j.drugalcdep.2010.02.017</infon><infon key="pub-id_pmid">20347232</infon><infon key="section_type">REF</infon><infon key="source">Drug and Alcohol Dependence</infon><infon key="type">ref</infon><infon key="volume">110</infon><infon key="year">2010</infon><offset>31495</offset><text>An improved brief measure of cannabis misuse: The Cannabis Use Disorders Identification Test-Revised (CUDIT-R)</text></passage><passage><infon key="fpage">716</infon><infon key="issue">4</infon><infon key="lpage">724</infon><infon key="name_0">surname:Amlung;given-names:M.</infon><infon key="name_1">surname:Acker;given-names:J.</infon><infon key="name_2">surname:Stojek;given-names:M.K.</infon><infon key="name_3">surname:Murphy;given-names:J.G.</infon><infon key="name_4">surname:MacKillop;given-names:J.</infon><infon key="pub-id_doi">10.1111/j.1530-0277.2011.01656.x</infon><infon key="section_type">REF</infon><infon key="source">Alcoholism, Clinical and Experimental Research</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2012</infon><offset>31606</offset><text>Is talk “cheap”? An initial investigation of the equivalence of alcohol purchase task performance for hypothetical and actual rewards</text></passage><passage><infon key="fpage">187</infon><infon key="lpage">191</infon><infon key="name_0">surname:Amlung;given-names:M.</infon><infon key="name_1">surname:MacKillop;given-names:J.</infon><infon key="pub-id_doi">10.1016/j.beproc.2015.02.012</infon><infon key="pub-id_pmid">25712039</infon><infon key="section_type">REF</infon><infon key="source">Behavioural Processes</infon><infon key="type">ref</infon><infon key="volume">113</infon><infon key="year">2015</infon><offset>31744</offset><text>Further evidence of close correspondence for alcohol demand decision making for hypothetical and incentivized rewards</text></passage><passage><infon key="fpage">168</infon><infon key="issue">3</infon><infon key="lpage">175</infon><infon key="name_0">surname:Amlung;given-names:M.</infon><infon key="name_1">surname:Yurasek;given-names:A.</infon><infon key="name_2">surname:McCarty;given-names:K.N.</infon><infon key="name_3">surname:MacKillop;given-names:J.</infon><infon key="name_4">surname:Murphy;given-names:J.G.</infon><infon key="pub-id_doi">10.1037/pha0000014</infon><infon key="pub-id_pmid">25895013</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2015</infon><offset>31862</offset><text>Area under the curve as a novel metric of behavioral economic demand for alcohol</text></passage><passage><infon key="fpage">42</infon><infon key="lpage">47</infon><infon key="name_0">surname:Aston;given-names:E.R.</infon><infon key="name_1">surname:Cassidy;given-names:R.N.</infon><infon key="pub-id_doi">10.1016/j.copsyc.2019.01.016</infon><infon key="pub-id_pmid">30807957</infon><infon key="section_type">REF</infon><infon key="source">Current Opinion in Psychology</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2019</infon><offset>31943</offset><text>Behavioral economic demand assessments in the addictions</text></passage><passage><infon key="fpage">2421</infon><infon key="issue">16</infon><infon key="lpage">2429</infon><infon key="name_0">surname:Aston;given-names:E.R.</infon><infon key="name_1">surname:Farris;given-names:S.G.</infon><infon key="name_2">surname:MacKillop;given-names:J.</infon><infon key="name_3">surname:Metrik;given-names:J.</infon><infon key="pub-id_doi">10.1007/s00213-017-4633-6</infon><infon key="pub-id_pmid">28508921</infon><infon key="section_type">REF</infon><infon key="source">Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">234</infon><infon key="year">2017</infon><offset>32000</offset><text>Latent factor structure of a behavioral economic marijuana demand curve</text></passage><passage><infon key="fpage">32</infon><infon key="lpage">38</infon><infon key="name_0">surname:Aston;given-names:E.R.</infon><infon key="name_1">surname:Metrik;given-names:J.</infon><infon key="name_2">surname:MacKillop;given-names:J.</infon><infon key="pub-id_doi">10.1016/j.drugalcdep.2015.04.025</infon><infon key="pub-id_pmid">26002377</infon><infon key="section_type">REF</infon><infon key="source">Drug and Alcohol Dependence</infon><infon key="type">ref</infon><infon key="volume">152</infon><infon key="year">2015</infon><offset>32072</offset><text>Further validation of a marijuana purchase task</text></passage><passage><infon key="fpage">23</infon><infon key="issue">1</infon><infon key="lpage">35</infon><infon key="name_0">surname:Aston;given-names:E.R.</infon><infon key="name_1">surname:Metrik;given-names:J.</infon><infon key="name_2">surname:Rosen;given-names:R.K.</infon><infon key="name_3">surname:Swift;given-names:R.</infon><infon key="name_4">surname:MacKillop;given-names:J.</infon><infon key="pub-id_doi">10.1037/pha0000355</infon><infon key="pub-id_pmid">32105138</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2021</infon><offset>32120</offset><text>Refining the Marijuana Purchase Task: Using qualitative methods to inform measure development</text></passage><passage><infon key="fpage">641</infon><infon key="issue">1</infon><infon key="lpage">677</infon><infon key="name_0">surname:Bickel;given-names:W.K.</infon><infon key="name_1">surname:Johnson;given-names:M.W.</infon><infon key="name_2">surname:Koffarnus;given-names:M.N.</infon><infon key="name_3">surname:MacKillop;given-names:J.</infon><infon key="name_4">surname:Murphy;given-names:J.G.</infon><infon key="pub-id_doi">10.1146/annurev-clinpsy-032813-153724</infon><infon key="section_type">REF</infon><infon key="source">Annual Review of Clinical Psychology</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2014</infon><offset>32214</offset><text>The behavioral economics of substance use disorders: Reinforcement pathologies and their repair</text></passage><passage><infon key="fpage">1257</infon><infon key="issue">11</infon><infon key="lpage">1263</infon><infon key="name_0">surname:Bidwell;given-names:L.C.</infon><infon key="name_1">surname:MacKillop;given-names:J.</infon><infon key="name_2">surname:Murphy;given-names:J.G.</infon><infon key="name_3">surname:Tidey;given-names:J.W.</infon><infon key="name_4">surname:Colby;given-names:S.M.</infon><infon key="pub-id_doi">10.1016/j.addbeh.2012.06.009</infon><infon key="pub-id_pmid">22727784</infon><infon key="section_type">REF</infon><infon key="source">Addictive Behaviors</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">2012</infon><offset>32310</offset><text>Latent factor structure of a behavioral economic cigarette demand curve in adolescent smokers</text></passage><passage><infon key="fpage">139</infon><infon key="lpage">144</infon><infon key="name_0">surname:Bohnert;given-names:K.M.</infon><infon key="name_1">surname:Bonar;given-names:E.E.</infon><infon key="name_2">surname:Arnedt;given-names:J.T.</infon><infon key="name_3">surname:Conroy;given-names:D.A.</infon><infon key="name_4">surname:Walton;given-names:M.A.</infon><infon key="name_5">surname:Ilgen;given-names:M.A.</infon><infon key="pub-id_doi">10.1016/j.addbeh.2017.08.001</infon><infon key="pub-id_pmid">28820970</infon><infon key="section_type">REF</infon><infon key="source">Addictive Behaviors</infon><infon key="type">ref</infon><infon key="volume">76</infon><infon key="year">2018</infon><offset>32404</offset><text>Utility of the comprehensive marijuana motives questionnaire among medical cannabis patients</text></passage><passage><infon key="fpage">136</infon><infon key="lpage">142</infon><infon key="name_0">surname:Bonar;given-names:E.E.</infon><infon key="name_1">surname:Goldstick;given-names:J.E.</infon><infon key="name_2">surname:Collins;given-names:R.L.</infon><infon key="name_3">surname:Cranford;given-names:J.A.</infon><infon key="name_4">surname:Cunningham;given-names:R.M.</infon><infon key="name_5">surname:Chermack;given-names:S.T.</infon><infon key="name_6">surname:Walton;given-names:M.A.</infon><infon key="pub-id_doi">10.1016/j.drugalcdep.2017.05.006</infon><infon key="pub-id_pmid">28647681</infon><infon key="section_type">REF</infon><infon key="source">Drug and Alcohol Dependence</infon><infon key="type">ref</infon><infon key="volume">178</infon><infon key="year">2017</infon><offset>32497</offset><text>Daily associations between cannabis motives and consumption in emerging adults</text></passage><passage><infon key="fpage">889</infon><infon key="issue">5</infon><infon key="lpage">897</infon><infon key="name_0">surname:Bruner;given-names:N.R.</infon><infon key="name_1">surname:Johnson;given-names:M.W.</infon><infon key="pub-id_doi">10.1007/s00213-013-3312-5</infon><infon key="pub-id_pmid">24217899</infon><infon key="section_type">REF</infon><infon key="source">Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">231</infon><infon key="year">2014</infon><offset>32576</offset><text>Demand curves for hypothetical cocaine in cocaine-dependent individuals</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>32648</offset><text>Canadian Centre on Substance Use and Addiction. (2020). COVID-19, Alcohol and Cannabis Use [report]. https://ccsa.ca/sites/default/files/2020-04/CCSA-COVID-19-Alcohol-Cannabis-Use-Report-2020-en.pdf.</text></passage><passage><infon key="fpage">211</infon><infon key="issue">3</infon><infon key="name_0">surname:Collins;given-names:R.L.</infon><infon key="name_1">surname:Vincent;given-names:P.C.</infon><infon key="name_2">surname:Yu;given-names:J.</infon><infon key="name_3">surname:Liu;given-names:L.</infon><infon key="name_4">surname:Epstein;given-names:L.H.</infon><infon key="pub-id_doi">10.1037/a0035318</infon><infon key="pub-id_pmid">24467370</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2014</infon><offset>32848</offset><text>A behavioral economic approach to assessing demand for marijuana</text></passage><passage><infon key="fpage">117</infon><infon key="issue">2</infon><infon key="lpage">128</infon><infon key="name_0">surname:Cooper;given-names:M.L.</infon><infon key="pub-id_doi">10.1037/1040-3590.6.2.117</infon><infon key="section_type">REF</infon><infon key="source">Psychological Assessment</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1994</infon><offset>32913</offset><text>Motivations for alcohol use among adolescents: Development and validation of a four-factor model</text></passage><passage><infon key="name_0">surname:Cooper;given-names:M.L.</infon><infon key="name_1">surname:Kuntsche;given-names:E.</infon><infon key="name_2">surname:Levitt;given-names:A.</infon><infon key="name_3">surname:Barber;given-names:L.L.</infon><infon key="name_4">surname:Wolf;given-names:S.</infon><infon key="name_5">surname:Sher;given-names:K.J.</infon><infon key="pub-id_doi">10.1093/oxfordhb/9780199381678.013.017</infon><infon key="section_type">REF</infon><infon key="series">The Oxford Handbook of Substance Use and Substance Use Disorders</infon><infon key="type">ref</infon><infon key="volume">Volume 1</infon><infon key="year">2016</infon><offset>33010</offset></passage><passage><infon key="fpage">e0178194</infon><infon key="issue">5</infon><infon key="name_0">surname:Cuttler;given-names:C.</infon><infon key="name_1">surname:Spradlin;given-names:A.</infon><infon key="name_2">surname:Ito;given-names:E.</infon><infon key="pub-id_doi">10.1371/journal.pone.0178194</infon><infon key="pub-id_pmid">28552942</infon><infon key="section_type">REF</infon><infon key="source">PloS One</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2017</infon><offset>33011</offset><text>Measuring cannabis consumption: Psychometric properties of the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU)</text></passage><passage><infon key="fpage">819</infon><infon key="issue">8</infon><infon key="lpage">826</infon><infon key="name_0">surname:Dennhardt;given-names:A.A.</infon><infon key="name_1">surname:Murphy;given-names:J.G.</infon><infon key="name_2">surname:McDevitt-Murphy;given-names:M.E.</infon><infon key="name_3">surname:Williams;given-names:J.L.</infon><infon key="pub-id_doi">10.1037/adb0000197</infon><infon key="pub-id_pmid">28068111</infon><infon key="section_type">REF</infon><infon key="source">Psychology of Addictive Behaviors</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2016</infon><offset>33164</offset><text>Drinking motives mediate the relationship between alcohol reward value and alcohol problems in military veterans</text></passage><passage><infon key="fpage">233</infon><infon key="issue">3</infon><infon key="lpage">239</infon><infon key="name_0">surname:Fritz;given-names:M.S.</infon><infon key="name_1">surname:MacKinnon;given-names:D.P.</infon><infon key="pub-id_doi">10.1111/j.1467-9280.2007.01882.x</infon><infon key="pub-id_pmid">17444920</infon><infon key="section_type">REF</infon><infon key="source">Psychological Science</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2007</infon><offset>33277</offset><text>Required sample size to detect the mediated effect</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>33328</offset><text>Government of Canada. (2017). Canadian Tobacco Alcohol and Drugs (CTADS) Survey: 2017 summary. https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2017-summary.html.</text></passage><passage><infon key="fpage">331</infon><infon key="issue">4</infon><infon key="lpage">335</infon><infon key="name_0">surname:Horesh;given-names:D.</infon><infon key="name_1">surname:Brown;given-names:A.D.</infon><infon key="pub-id_doi">10.1037/TRA0000592</infon><infon key="section_type">REF</infon><infon key="source">Psychological Trauma: Theory, Research, Practice, and Policy</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2020</infon><offset>33528</offset><text>Traumatic stress in the age of COVID-19: A call to close critical gaps and adapt to new realities</text></passage><passage><infon key="fpage">1</infon><infon key="issue">1</infon><infon key="lpage">55</infon><infon key="name_0">surname:Hu;given-names:L.T.</infon><infon key="name_1">surname:Bentler;given-names:P.M.</infon><infon key="pub-id_doi">10.1080/10705519909540118</infon><infon key="section_type">REF</infon><infon key="source">Structural Equation Modeling</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1999</infon><offset>33626</offset><text>Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives</text></passage><passage><infon key="fpage">186</infon><infon key="issue">1</infon><infon key="lpage">198</infon><infon key="name_0">surname:Hursh;given-names:S.R.</infon><infon key="name_1">surname:Silberberg;given-names:A.</infon><infon key="pub-id_doi">10.1037/0033-295X.115.1.186</infon><infon key="pub-id_pmid">18211190</infon><infon key="section_type">REF</infon><infon key="source">Psychological Review</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">2008</infon><offset>33738</offset><text>Economic demand and essential value</text></passage><passage><infon key="fpage">400</infon><infon key="issue">4</infon><infon key="lpage">413</infon><infon key="name_0">surname:Hyman;given-names:S.M.</infon><infon key="name_1">surname:Sinha;given-names:R.</infon><infon key="pub-id_doi">10.1016/j.jsat.2008.08.005</infon><infon key="pub-id_pmid">19004601</infon><infon key="section_type">REF</infon><infon key="source">Journal of Substance Abuse Treatment</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2009</infon><offset>33774</offset><text>Stress-related factors in cannabis use and misuse: Implications for prevention and treatment</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>33867</offset><text>Imtiaz, S., Wells, S., Rehm, J., Hamilton, H. A., Nigatu, Y. T., Wickens, C. M., Jankowicz, D., &amp; Elton-Marshall, T. (2020). Cannabis use during the COVID-19 pandemic in Canada. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000798.</text></passage><passage><infon key="fpage">412</infon><infon key="issue">4</infon><infon key="lpage">426</infon><infon key="name_0">surname:Jacobs;given-names:E.A.</infon><infon key="name_1">surname:Bickel;given-names:W.K.</infon><infon key="pub-id_doi">10.1037//1064-1297.7.4.412</infon><infon key="pub-id_pmid">10609976</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1999</infon><offset>34122</offset><text>Modeling drug consumption in the clinic using simulation procedures: Demand for heroin and cigarettes in opioid-dependent outpatients</text></passage><passage><infon key="name_0">surname:Kline;given-names:R.B.</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2005</infon><offset>34256</offset></passage><passage><infon key="fpage">179</infon><infon key="issue">3</infon><infon key="lpage">189</infon><infon key="name_0">surname:Kwako;given-names:L.E.</infon><infon key="name_1">surname:Momenan;given-names:R.</infon><infon key="name_2">surname:Litten;given-names:R.Z.</infon><infon key="name_3">surname:Koob;given-names:G.F.</infon><infon key="name_4">surname:Goldman;given-names:D.</infon><infon key="pub-id_doi">10.1016/j.biopsych.2015.10.024</infon><infon key="pub-id_pmid">26772405</infon><infon key="section_type">REF</infon><infon key="source">Biological Psychiatry</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">2016</infon><offset>34257</offset><text>Addictions Neuroclinical Assessment: A neuroscience-based framework for addictive disorders</text></passage><passage><infon key="fpage">1384</infon><infon key="issue">7</infon><infon key="lpage">1394</infon><infon key="name_0">surname:Lee;given-names:C.M.</infon><infon key="name_1">surname:Neighbors;given-names:C.</infon><infon key="name_2">surname:Woods;given-names:B.A.</infon><infon key="pub-id_doi">10.1016/j.addbeh.2006.09.010</infon><infon key="pub-id_pmid">17097817</infon><infon key="section_type">REF</infon><infon key="source">Addictive Behaviors</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2007</infon><offset>34349</offset><text>Marijuana motives: Young adults’ reasons for using marijuana</text></passage><passage><infon key="fpage">265</infon><infon key="issue">3</infon><infon key="lpage">270</infon><infon key="name_0">surname:Luciano;given-names:M.T.</infon><infon key="name_1">surname:Acuff;given-names:S.F.</infon><infon key="name_2">surname:McDevitt-Murphy;given-names:M.E.</infon><infon key="name_3">surname:Murphy;given-names:J.G.</infon><infon key="pub-id_doi">10.1037/pha0000318</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2020</infon><offset>34412</offset><text>Behavioral economics and coping-related drinking motives in trauma exposed drinkers: Implications for the self-medication hypothesis</text></passage><passage><infon key="fpage">1426</infon><infon key="issue">12</infon><infon key="lpage">1434</infon><infon key="name_0">surname:MacKillop;given-names:J.</infon><infon key="name_1">surname:Brown;given-names:C.L.</infon><infon key="name_2">surname:Stojek;given-names:M.K.</infon><infon key="name_3">surname:Murphy;given-names:C.M.</infon><infon key="name_4">surname:Sweet;given-names:L.</infon><infon key="name_5">surname:Niaura;given-names:R.S.</infon><infon key="pub-id_doi">10.1093/ntr/nts006</infon><infon key="pub-id_pmid">22416117</infon><infon key="section_type">REF</infon><infon key="source">Nicotine and Tobacco Research</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2012</infon><offset>34545</offset><text>Behavioral economic analysis of withdrawal- and cue-elicited craving for tobacco: An initial investigation</text></passage><passage><infon key="fpage">57</infon><infon key="issue">1</infon><infon key="lpage">65</infon><infon key="name_0">surname:MacKillop;given-names:J.</infon><infon key="name_1">surname:Murphy;given-names:J.G.</infon><infon key="name_2">surname:Ray;given-names:L.A.</infon><infon key="name_3">surname:Eisenberg;given-names:D.T.A.</infon><infon key="name_4">surname:Lisman;given-names:S.A.</infon><infon key="name_5">surname:Lum;given-names:J.K.</infon><infon key="name_6">surname:Wilson;given-names:D.S.</infon><infon key="pub-id_doi">10.1037/1064-1297.16.1.57</infon><infon key="pub-id_pmid">18266552</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2008</infon><offset>34652</offset><text>Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers</text></passage><passage><infon key="fpage">33</infon><infon key="issue">1</infon><infon key="lpage">40</infon><infon key="name_0">surname:MacKillop;given-names:J.</infon><infon key="name_1">surname:Murphy;given-names:J.G.</infon><infon key="name_2">surname:Tidey;given-names:J.W.</infon><infon key="name_3">surname:Kahler;given-names:C.W.</infon><infon key="name_4">surname:Ray;given-names:L.A.</infon><infon key="name_5">surname:Bickel;given-names:W.K.</infon><infon key="pub-id_doi">10.1007/s00213-008-1367-5</infon><infon key="pub-id_pmid">18925387</infon><infon key="section_type">REF</infon><infon key="source">Psychopharmacology (Berl)</infon><infon key="type">ref</infon><infon key="volume">203</infon><infon key="year">2009</infon><offset>34779</offset><text>Latent structure of facets of alcohol reinforcement from a behavioral economic demand curve</text></passage><passage><infon key="issue">3</infon><infon key="name_0">surname:Marjanovic;given-names:Z.</infon><infon key="name_1">surname:Struthers;given-names:C.W.</infon><infon key="name_2">surname:Cribbie;given-names:R.</infon><infon key="name_3">surname:Greenglass;given-names:E.R.</infon><infon key="pub-id_doi">10.1177/2158244014545964</infon><infon key="section_type">REF</infon><infon key="source">SAGE Open</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2014</infon><offset>34871</offset><text>The Conscientious Responders Scale: A new tool for discriminating between conscientious and random responders</text></passage><passage><infon key="fpage">929</infon><infon key="issue">6</infon><infon key="lpage">934</infon><infon key="name_0">surname:Morris;given-names:V.</infon><infon key="name_1">surname:Patel;given-names:H.</infon><infon key="name_2">surname:Vedelago;given-names:L.</infon><infon key="name_3">surname:Reed;given-names:D.D.</infon><infon key="name_4">surname:Metrik;given-names:J.</infon><infon key="name_5">surname:Aston;given-names:E.</infon><infon key="name_6">surname:Amlung;given-names:M.</infon><infon key="pub-id_doi">10.15288/jsad.2018.79.929</infon><infon key="pub-id_pmid">30573024</infon><infon key="section_type">REF</infon><infon key="source">Journal of Studies on Alcohol and Drugs</infon><infon key="type">ref</infon><infon key="volume">79</infon><infon key="year">2018</infon><offset>34981</offset><text>Elevated behavioral economic demand for alcohol in co-users of alcohol and cannabis</text></passage><passage><infon key="fpage">219</infon><infon key="issue">2</infon><infon key="lpage">227</infon><infon key="name_0">surname:Murphy;given-names:J.G.</infon><infon key="name_1">surname:MacKillop;given-names:J.</infon><infon key="pub-id_doi">10.1037/1064-1297.14.2.219</infon><infon key="pub-id_pmid">16756426</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2006</infon><offset>35065</offset><text>Relative reinforcing efficacy of alcohol among college student drinkers</text></passage><passage><infon key="name_0">surname:Muthén;given-names:L.K.</infon><infon key="name_1">surname:Muthén;given-names:B.O.</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2012</infon><offset>35137</offset></passage><passage><infon key="fpage">22</infon><infon key="lpage">27</infon><infon key="name_0">surname:Palan;given-names:S.</infon><infon key="name_1">surname:Schitter;given-names:C.</infon><infon key="pub-id_doi">10.1016/j.jbef.2017.12.004</infon><infon key="section_type">REF</infon><infon key="source">Journal of Behavioral and Experimental Finance</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2018</infon><offset>35138</offset><text>Prolific. ac—A subject pool for online experiments</text></passage><passage><infon key="fpage">109</infon><infon key="issue">2</infon><infon key="lpage">114</infon><infon key="name_0">surname:Patel;given-names:H.</infon><infon key="name_1">surname:Amlung;given-names:M.</infon><infon key="pub-id_doi">10.1037/pha0000240</infon><infon key="pub-id_pmid">30475012</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2019</infon><offset>35191</offset><text>Elevated cannabis demand is associated with driving after cannabis use in a crowd-sourced sample of adults</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>35298</offset><text>Prolific Team. (2018). Using attention checks as a measure of data quality. https://researcher-help.prolific.co/hc/en-gb/articles/360009223553-Using-attention-checks-as-a-measure-of-data-quality.</text></passage><passage><infon key="fpage">113407</infon><infon key="name_0">surname:Rogers;given-names:A.H.</infon><infon key="name_1">surname:Shepherd;given-names:J.M.</infon><infon key="name_2">surname:Garey;given-names:L.</infon><infon key="name_3">surname:Zvolensky;given-names:M.J.</infon><infon key="pub-id_doi">10.1016/j.psychres.2020.113407</infon><infon key="pub-id_pmid">32827993</infon><infon key="section_type">REF</infon><infon key="source">Psychiatry Research</infon><infon key="type">ref</infon><infon key="volume">293</infon><infon key="year">2020</infon><offset>35494</offset><text>Psychological factors associated with substance use initiation during the COVID-19 pandemic</text></passage><passage><infon key="fpage">265</infon><infon key="issue">3</infon><infon key="lpage">273</infon><infon key="name_0">surname:Simons;given-names:J.</infon><infon key="name_1">surname:Correia;given-names:C.J.</infon><infon key="name_2">surname:Carey;given-names:K.B.</infon><infon key="name_3">surname:Borsari;given-names:B.E.</infon><infon key="pub-id_doi">10.1037/0022-0167.45.3.265</infon><infon key="section_type">REF</infon><infon key="source">Journal of Counseling Psychology</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">1998</infon><offset>35586</offset><text>Validating a five-factor marijuana motives measure: Relations with use, problems, and alcohol motives</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>35688</offset><text>Statistics Canada. (2020). Retail trade sales by province and territory. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=2010000801&amp;pickMembers%5B0%5D=2.30&amp;pickMembers%5B1%5D=3.1&amp;cubeTimeFrame.startMonth=09&amp;cubeTimeFrame.startYear=2020&amp;cubeTimeFrame.endMonth=10&amp;cubeTimeFrame.endYear=2020&amp;referencePeriods=20200901%2C20201.</text></passage><passage><infon key="fpage">377</infon><infon key="issue">5</infon><infon key="lpage">386</infon><infon key="name_0">surname:Stein;given-names:J.S.</infon><infon key="name_1">surname:Koffarnus;given-names:M.N.</infon><infon key="name_2">surname:Snider;given-names:S.E.</infon><infon key="name_3">surname:Quisenberry;given-names:A.J.</infon><infon key="name_4">surname:Bickel;given-names:W.K.</infon><infon key="pub-id_doi">10.1037/pha0000020</infon><infon key="pub-id_pmid">26147181</infon><infon key="section_type">REF</infon><infon key="source">Experimental and Clinical Psychopharmacology</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2015</infon><offset>36018</offset><text>Identification and management of nonsystematic purchase task data: Toward best practice</text></passage><passage><infon key="fpage">898</infon><infon key="issue">5</infon><infon key="lpage">908</infon><infon key="name_0">surname:Stephens;given-names:R.S.</infon><infon key="name_1">surname:Roffman;given-names:R.A.</infon><infon key="name_2">surname:Curtin;given-names:L.</infon><infon key="pub-id_pmid">11068976</infon><infon key="section_type">REF</infon><infon key="source">Journal of Consulting and Clinical Psychology</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2000</infon><offset>36106</offset><text>Comparison of extended versus brief treatments for marijuana use</text></passage><passage><infon key="fpage">33</infon><infon key="lpage">40</infon><infon key="name_0">surname:Strickland;given-names:J.C.</infon><infon key="name_1">surname:Lile;given-names:J.A.</infon><infon key="name_2">surname:Stoops;given-names:W.W.</infon><infon key="pub-id_doi">10.1016/j.beproc.2017.03.017</infon><infon key="pub-id_pmid">28347716</infon><infon key="section_type">REF</infon><infon key="source">Behavioural Processes</infon><infon key="type">ref</infon><infon key="volume">140</infon><infon key="year">2017</infon><offset>36171</offset><text>Unique prediction of cannabis use severity and behaviors by delay discounting and behavioral economic demand</text></passage><passage><infon key="name_0">surname:Tabachnick;given-names:B.G.</infon><infon key="name_1">surname:Fidell;given-names:L.S.</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2004</infon><offset>36280</offset></passage><passage><infon key="fpage">42</infon><infon key="issue">3</infon><infon key="lpage">50</infon><infon key="name_0">surname:Teeters;given-names:J.B.</infon><infon key="name_1">surname:Meshesha;given-names:L.Z.</infon><infon key="name_2">surname:Dennhardt;given-names:A.A.</infon><infon key="name_3">surname:Murphy;given-names:J.G.</infon><infon key="pub-id_doi">10.1097/CXA.0000000000000062</infon><infon key="section_type">REF</infon><infon key="source">Canadian Journal of Addiction</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2019</infon><offset>36281</offset><text>Elevated demand and proportionate substance-related reinforcement are associated with driving after cannabis use</text></passage><passage><infon key="fpage">1956</infon><infon key="issue">11</infon><infon key="lpage">1965</infon><infon key="name_0">surname:Tucker;given-names:J.A.</infon><infon key="name_1">surname:Cheong;given-names:J.</infon><infon key="name_2">surname:Chandler;given-names:S.D.</infon><infon key="name_3">surname:Lambert;given-names:B.H.</infon><infon key="name_4">surname:Kwok;given-names:H.</infon><infon key="name_5">surname:Pietrzak;given-names:B.</infon><infon key="pub-id_doi">10.1111/add.v111.1110.1111/add.13492</infon><infon key="pub-id_pmid">27318078</infon><infon key="section_type">REF</infon><infon key="source">Addiction</infon><infon key="type">ref</infon><infon key="volume">111</infon><infon key="year">2016</infon><offset>36394</offset><text>Behavioral economic indicators of drinking problem severity and initial outcomes among problem drinkers attempting natural recovery: A cross-sectional naturalistic study</text></passage><passage><infon key="fpage">2219</infon><infon key="issue">23</infon><infon key="lpage">2227</infon><infon key="name_0">surname:Volkow;given-names:N.D.</infon><infon key="name_1">surname:Baler;given-names:R.D.</infon><infon key="name_2">surname:Compton;given-names:W.M.</infon><infon key="name_3">surname:Weiss;given-names:S.R.B.</infon><infon key="pub-id_doi">10.1056/nejmra1402309</infon><infon key="section_type">REF</infon><infon key="source">New England Journal of Medicine</infon><infon key="type">ref</infon><infon key="volume">370</infon><infon key="year">2014</infon><offset>36564</offset><text>Adverse health effects of marijuana use</text></passage><passage><infon key="fpage">2073</infon><infon key="issue">10</infon><infon key="lpage">2083</infon><infon key="name_0">surname:Wardell;given-names:J.D.</infon><infon key="name_1">surname:Kempe;given-names:T.</infon><infon key="name_2">surname:Rapinda;given-names:K.K.</infon><infon key="name_3">surname:Single;given-names:A.</infon><infon key="name_4">surname:Bilevicius;given-names:E.</infon><infon key="name_5">surname:Frolich;given-names:J.R.</infon><infon key="name_6">surname:Keough;given-names:M.T.</infon><infon key="pub-id_doi">10.1111/acer.14425</infon><infon key="section_type">REF</infon><infon key="source">Alcoholism: Clinical and Experimental Research</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2020</infon><offset>36604</offset><text>Drinking to cope during COVID-19 pandemic: The role of external and internal factors in coping motive pathways to alcohol use, solitary drinking, and alcohol problems</text></passage><passage><infon key="fpage">991</infon><infon key="issue">6</infon><infon key="lpage">999</infon><infon key="name_0">surname:Yurasek;given-names:A.M.</infon><infon key="name_1">surname:Murphy;given-names:J.G.</infon><infon key="name_2">surname:Dennhardt;given-names:A.A.</infon><infon key="name_3">surname:Skidmore;given-names:J.R.</infon><infon key="name_4">surname:Buscemi;given-names:J.</infon><infon key="name_5">surname:McCausland;given-names:C.</infon><infon key="name_6">surname:Martens;given-names:M.P.</infon><infon key="pub-id_doi">10.15288/jsad.2011.72.991</infon><infon key="pub-id_pmid">22051213</infon><infon key="section_type">REF</infon><infon key="source">Journal of Studies on Alcohol and Drugs</infon><infon key="type">ref</infon><infon key="volume">72</infon><infon key="year">2011</infon><offset>36771</offset><text>Drinking motives mediate the relationship between reinforcing efficacy and alcohol consumption and problems</text></passage><passage><infon key="fpage">3122</infon><infon key="issue">12</infon><infon key="lpage">3130</infon><infon key="name_0">surname:Zvolensky;given-names:M.J.</infon><infon key="name_1">surname:Vujanovic;given-names:A.A.</infon><infon key="name_2">surname:Bernstein;given-names:A.</infon><infon key="name_3">surname:Bonn-Miller;given-names:M.O.</infon><infon key="name_4">surname:Marshall;given-names:E.C.</infon><infon key="name_5">surname:Leyro;given-names:T.M.</infon><infon key="pub-id_doi">10.1016/j.addbeh.2007.06.010</infon><infon key="pub-id_pmid">17602842</infon><infon key="section_type">REF</infon><infon key="source">Addictive Behaviors</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2007</infon><offset>36879</offset><text>Marijuana use motives: A confirmatory test and evaluation among young adult marijuana users</text></passage><passage><infon key="section_type">REF</infon><infon key="type">footnote</infon><offset>36971</offset><text>Given that greater than 50% of our sample reprted having an annual household income of greater than $80,000, we examined the bivariate correlations between income and all cannabis-related variables. We found that income was uncorrelated with all cannabis variables, and thus, we opted not to include it in the main path analysis.</text></passage></document></collection>
